Revelation Biosciences Inc (REVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,403 | -4,496 | -2,051 | -15,039 | -13,313 |
| Depreciation Amortization | 21 | 14 | 7 | 28 | 21 |
| Accounts payable and accrued liabilities | 236 | 45 | -159 | -576 | 1,768 |
| Other Working Capital | -156 | -462 | -979 | -3,423 | -1,324 |
| Other Operating Activity | -2 | 184 | 387 | 689 | -1,725 |
| Operating Cash Flow | $-6,303 | $-4,714 | $-2,794 | $-18,321 | $-14,574 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -19 | -37 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $-19 | $-37 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 12,512 | 3,389 | N/A | 12,848 | 9,160 |
| Financing Cash Flow | $12,512 | $3,389 | $N/A | $12,848 | $9,160 |
| Beginning Cash Position | 6,499 | 6,499 | 6,499 | 11,992 | 11,992 |
| End Cash Position | 12,709 | 5,174 | 3,705 | 6,499 | 6,541 |
| Net Cash Flow | $6,210 | $-1,325 | $-2,794 | $-5,493 | $-5,451 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,303 | -4,714 | -2,794 | -18,321 | -14,574 |
| Capital Expenditure | N/A | N/A | N/A | -19 | -37 |
| Free Cash Flow | -6,303 | -4,714 | -2,794 | -18,341 | -14,611 |